Evolus announces FDA approval of Evolysse products

Evolus (EOLS) announced that the Food and Drug Administration has approved Evolysse Form and Evolysse Smooth injectable hyaluronic acid gels, the first two products in the Evolysse collection. “These approvals mark Evolus’ entry into the U.S. HA dermal filler market,” the company stated. Evolus plans to launch Evolysse Form and Evolysse Smooth in the U.S. market in Q2. “This launch will leverage Evolus’ scalable cash-pay business model and existing digital infrastructure, creating tremendous synergy with the company’s fast-growing neurotoxin business and driving significant value for both customers and consumers,” the company stated.